Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2008
10/23/2008WO2008041118A3 Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
10/23/2008WO2008040995A8 Indazoles for use as dpp-iv inhibitors
10/23/2008WO2008040000A3 Soluble epoxide hydrolase inhibitors
10/23/2008WO2008035315A9 Inhibitors of phosphodiesterase type-iv
10/23/2008WO2008030853A3 Combination therapy for human immunodeficiency virus infection
10/23/2008WO2008029300A3 Methods for treating at least one condition having mt1 receptor, 5ht2b receptor, and l-type calcium channel activity
10/23/2008WO2008028060A3 Anti-tumor compounds for inhibiting cancer growth
10/23/2008WO2008024970A3 Tetrahydroindolone and tetrahydroindazolone derivatives
10/23/2008WO2008024242A3 Use of cd83 in combination therapies
10/23/2008WO2008023277A3 Compositions containing coenzyme q-10 and dihydrolipoic acid
10/23/2008WO2008021829A3 Topical ceramide compositions and methos of use
10/23/2008WO2008011204A3 Self-assembling protein hydrogel with bio-active protein
10/23/2008WO2008011073A3 Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
10/23/2008WO2008008986A3 Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration
10/23/2008WO2008007113A3 Pharmaceutical combinations
10/23/2008WO2008006607A3 Pharmaceutical and nutraceutical products comprising vitamin k2
10/23/2008WO2008005819A3 Ophthalmic formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
10/23/2008WO2008002600A3 Biosynthesis of salinosporamide a and analogs and methods thereof
10/23/2008WO2007148309A3 Compositions and kits comprising a melatonin component and a flavanol component
10/23/2008WO2007148308A3 Compositions and kits comprising a melatonin component and an omega-3-fatty acid component
10/23/2008WO2007146185A3 Uses of lectin-conotoxin
10/23/2008WO2007144720A3 Ccr5 antagonist for enhancing immune reconstitution and treating opportunistic infection in hiv patients
10/23/2008WO2007140228A3 Nicotine-alternative compositions and methods of producing such compositions
10/23/2008WO2007137156A3 Rnai modulation of aha and therapeutic uses thereof
10/23/2008WO2007136921A8 Small molecule apoptosis promoters
10/23/2008WO2007127145A3 Methods and compositions for treatment of cardiac arrhythmia in non-human animals
10/23/2008WO2007126898A3 Use of ladostigil for the treatment of schizophrenia
10/23/2008WO2007126653A3 Smooth muscle relaxation
10/23/2008WO2007124489A3 Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines
10/23/2008WO2007124331A3 Cardioprotective and other uses of mammalian target of rapamycin (m-tor) inhibitors
10/23/2008WO2007117438A3 Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith
10/23/2008WO2007106415A3 Triggered self-assembly conjugates and nanosystems
10/23/2008WO2007106381A3 Ophthalmic compositions comprising povidone-iodine
10/23/2008WO2007080325A8 Fgf-receptor agonist dimeric compounds
10/23/2008WO2007079960A9 Substituted thiazoles and their use for producing drugs
10/23/2008WO2007075852A3 Calcium channel antagonists
10/23/2008WO2007062093A3 Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
10/23/2008WO2007046022A3 Inhibitors of phosphodiesterase type-iv
10/23/2008WO2006135799A3 Detection of hookworm coproantigens
10/23/2008US20080263689 Screening/monitoring rate of internalization of insulin receptors in insulin-stimulated hepatocytes; identifying modulators of insulin clearance and secretion; treating insulin resistance
10/23/2008US20080263607 Downloading and Transfer of Audio or Video Data from Video Broadcasts
10/23/2008US20080262445 Adding polyethylene glycol and tocopherols to a hydrophobic active agent of N-lauroyl sarcosine; solubilizing the bioactive agent, enhancing permeation across the skin; drug delivery; patch
10/23/2008US20080262444 Percutaneously Absorbable Preparation, Percutaneously Absorbable Preparation Holding Sheet, and Percutaneously Absorbable Preparation Holding Equipment
10/23/2008US20080262411 treatment of obesity by electrical activation or deactivation of the nervous system, using electrodes, then further performing surgery and administering anorexigenic agents
10/23/2008US20080262286 using methyl arachidonyl fluorophosphonate (MAFP) and arachidonyl trifluoromethyl ketone (AACOCF3) as cytosolic phospholipase A2 (cPLA2) antagonist, a vector encoding a cytosolic phospholipase antagonist; tumor growth suppression; ionizing radiation; small interfering RNA targeted to cPLA2 gene product
10/23/2008US20080262284 Disposable products ; multilayer; interior and exterior layers forming reservoirs; heat activated adhesives; sealing; colorimetric analysis
10/23/2008US20080262229 Analgesics; pain management
10/23/2008US20080262228 Therapy for central nervous system disorders; Alzheimer's disease; 5-fluoro-8-(4-(4-(6-methoxyquinolin-8-) piperazin-1-yl )piperidin-1-yl)quinoline
10/23/2008US20080262221 (PYRIDO/THIENO)-[f]-OXAZEPINE-5-ONE DERIVATIVES
10/23/2008US20080262210 Immunostimulating Agents
10/23/2008US20080262205 Unphosphorylated glycogen synthase kinase-3-g-beta (GSK) from baculovirus overexpression system; competitive binding; diabetes, Alzheimer's disease
10/23/2008US20080262099 Administering cannabidiol produced from a given cannabis chemovar and in the form of a botanical drug substance; modulators motility of glioma cell motility; uneffected by involvement of cannabinoid receptor antagonists; antitumor, anticarcinogenic, antiproliferative and antimetastsis agents.
10/23/2008US20080262097 Formulations
10/23/2008US20080262096 Squaric Acid Derivatives
10/23/2008US20080262095 Protectant for UV-Induced Skin Damage
10/23/2008US20080262094 Administering tramadol and a phosphodiesterase (PDE) inhibitor to the male an effective time prior to sexual activity; PDE5 inhibitors of sildenafil citrate, vardenafil hydrochloride and/or tadalafil; kits; sexual/urogennital disorders
10/23/2008US20080262093 Contacting a cell expressing PGC-1 with various amount of respiration uncoupling agent to determing the resulting maximum PGC-1 level and therefore the upper limit of the safe dosage for the agent; decreasing fat mass/adipocity or increasing weight loss; antidiabetic agents; eating/metabolic disorders
10/23/2008US20080262092 Regulation of osteopontin
10/23/2008US20080262091 Analgesic/antinociceptive agents comprising 1-15,000mu g of capsaicin and other capsaicinoids in a vehicle; side effect reduction; neuropathic pain; neurotransmitter-dysregulation syndromes; incapacitation of C-fibers and/or A-delta fibers; denervate edges without eliciting an effect outside the edge
10/23/2008US20080262090 Guanylhydrazone Salts, Compositions, Processes of Making, and Methods of Using
10/23/2008US20080262089 Process for the Preparation of Tamsulosin
10/23/2008US20080262088 Methods, compounds, and compositions for treating metabolic disorders and diabetes
10/23/2008US20080262087 Modified g-protein coupled receptor for identifying modulators of taste preception; artificial sweeteners
10/23/2008US20080262086 Substituted anthranilic acids
10/23/2008US20080262084 Stable Emulsion Compositions for Intravenous Administration Having Preservatie Efficacy
10/23/2008US20080262083 A stereoisomer of a"Fenicol compound" (a chloramphenicol), D-(threo)-1-aryl-2-disubstituted-acylamido-3-fluoro-1-propanols; broad spectrum anibiotic with greater bioavailability; veterinary medicine; testing and administering the stereoisomer which clears more slowly; side effect reduction; nontoxic
10/23/2008US20080262082 S-(-)-tulipalin B, acetylated-S-(-)-tulipalin B and an antibacterial composition comprising the same. The active compound tulipalin B and composition of the present invention exhibit superior and stable antibacterial activity over a broad range of temperature and pH
10/23/2008US20080262081 of resveratrol, a derivative, metabolite or analogue thereof, in combination with at least one additional component selected from EGCG, coenzyme Q-IO, genistein, lycopene, hydroxytyrosol and polyunsaturated fatty acids in the manufacture of a nutraceutical composition for delaying aging
10/23/2008US20080262080 Allergy Suppressive Agent
10/23/2008US20080262079 Cannabinoid Compositions and Methods of Use Thereof
10/23/2008US20080262078 Pharmaceutical Compositions
10/23/2008US20080262077 Pharmaceutical formulations containing lipoic acid derivatives
10/23/2008US20080262076 Novel Tetracyclic Tetrahydrofuran Derivatives Containing Cyclic Amine Side Chain
10/23/2008US20080262075 Pyrrolidine Derivatives as Muscarinic Receptor Antagonists
10/23/2008US20080262074 salt forms of [R (R*,R*)]-2-(4-fluorophenyl)- beta , delta -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid or solvates or hydrates thereof, as well as crystalline salts characterized by their X-ray powder diffraction pattern are described
10/23/2008US20080262073 Pyrrolic Derivatives with Histone Deacetylase Inhibitory Activity
10/23/2008US20080262072 Compositions And Kits Comprising A Melatonin Component And A Flavanol Component
10/23/2008US20080262071 Pindolol for the Treating Premenstrual Syndrome and Premenstrual Dysphoric Disorder
10/23/2008US20080262070 compounds which mediate the activity of LFA-1 with its ligands involved in cell adhesion, migration and activation.
10/23/2008US20080262069 carvedilol phosphate salts, which include novel crystalline forms of carvedilol dihydrogen phosphate (i.e., dihydrogen phosphate salt of 1-(carbazol-4-yloxy-3-[[2-(o-methoxyphenoxy) ethyl]amino]-2-propanol) and/or carvedilol hydrogen phosphate, etc.), and/or solvates , compositions containing compounds
10/23/2008US20080262068 Method of Tonic Treatment With Oxyphenbutazone Derivatives
10/23/2008US20080262067 pharmaceutical composition comprising idazoxan or derivatives and their therapeutically acceptable salts, racemates, optically active isomers and polymorphs.
10/23/2008US20080262066 azole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders.
10/23/2008US20080262065 Novel inhibitors of glutaminyl cyclases
10/23/2008US20080262064 Novel Compounds For The Treatment Of GI Disorders 682
10/23/2008US20080262063 Novel inhibitors of glutaminyl cyclase
10/23/2008US20080262062 disease treatable with PARP modulators by identifying a level of PARP in a plurality of samples from a population, making a decision regarding identifying the disease treatable by the PARP modulators wherein the decision is made based on the level of PARP
10/23/2008US20080262060 novel crystalline forms of deferasirox, methods for their production, and methods for conversion of the novel forms to the known crystalline form I.
10/23/2008US20080262059 AT 1-antagonist vaisertan or a pharmaceutically acceptable salt thereof; and(ii) a NEP inhibitor or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier and to a method for the treatment or prevention of a condition or diseaseselected from hypertension
10/23/2008US20080262058 Inhibitors of HCV replication of formula (I)** Image-1whereinW is a heterocycle of formula** Image-2and the remaining variables are as defined in the specification.
10/23/2008US20080262056 (S) N-[3-(1-methyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide; staphylococci, streptococci, Enterococci, Haemophilus, Moraxella, bacteroides, clostridia, Mycobacteria, or Chlamydia
10/23/2008US20080262055 Macrocyclic Acyl Guanidines as Beta-Secretase Inhibitors
10/23/2008US20080262054 Pharmaceutical Composition Containing Thiazolidinedione Compound
10/23/2008US20080262053 continuous treatment with pramipexole even over 6 months or more leads to a lasting improvement in the RLS symptoms
10/23/2008US20080262052 disorders of lipid and/or carbohydrate metabolism, metabolic disorders, central nervous system disorders; 3-{2-Chloro-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazole-5-ylmethoxy]-phenyl}-4H-[1,2,4]oxadiazole-5-one
10/23/2008US20080262051 5-(1,1-Difluoroethyl)-3-(4-{4-methyl-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazol-3-yl}bicyclo[2.2.2]oct-1-yl)-1,2,4-oxadiazole; inhibitors of the Sonic Hedgehog pathway; prostate, non-small cell lung cancers, gastrointestinal cancer and bladder cancer
10/23/2008US20080262050 Organic Compounds
10/23/2008US20080262049 Therapeutic Agent for Hematopoietic Tumor
10/23/2008US20080262048 Control of parasites in animals by the use of novel trifluoromethanesulfonanilide oxime ether derivatives
10/23/2008US20080262047 Ppar-Gamma Agonists for Improvement of Cognitive Function in Apoe4 Negative Patients
1 ... 3028 3029 3030 3031 3032 3033 3034 3035 3036 3037 3038 3039 3040 3041 3042 3043 3044 3045 3046 3047 3048 ... 7860